AC
VNDA icon

Aristides Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Aristides Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-64,383
Closed -$272K – 369
2023
Q4 		$272K Buy
+64,383
New +$260K 0.1% 144

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristides Capital's VNDA Position: Q1 2024 in Review

Aristides Capital sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 64,383 shares — an estimated $272K sold.

Aristides Capital first reported a position in VNDA in Q4 2023 and held it in 1 quarter. The position peaked at $272K in Q4 2023. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.

  • Aristides Capital reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Aristides Capital sold 64,383 Vanda Pharmaceuticals shares in Q1 2024, an estimated $272K.
  • Aristides Capital first reported a position in Vanda Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Aristides Capital's Vanda Pharmaceuticals position peaked at $272K in Q4 2023.
  • 144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.

Based on Aristides Capital's 13F filing for Q1 2024, filed 15 May 2024.